Although not currently an approved therapy for asthma, treatment with the anti-IL-13 mAb lebrikizumab reduced subepithelial collagen thickness in patients with uncontrolled asthma, providing further evidence of a role for IL-13 in airway remodelling [161]. This evidence concerns the gene IL13 and asthma.